Share Email Print
cover

Proceedings Paper

A paradigm shift in chronic wound assessment: incorporating bacterial fluorescence imaging into standard of care
Author(s): Thomas E. Serena
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

The clinical signs and symptoms of infection in acute and chronic wounds are unreliable. Similarly, swab cultures are inaccurate in this population. Tissue biopsies and polymerase chain reaction (PCR) are more accurate but the results require several days to obtain. As a result, the clinician is forced to treat patients empirically. This has led to the overuse of antibiotics and the failure of advanced therapies due to unrecognized infection. To address this problem a point-ofcare diagnostic was developed to identify bacteria in acute and chronic wounds. The MolecuLight procedure (MiX) exposes the wound bed to violet light at 405 nm. Bacterial fluorophores absorb the light. In turn they fluoresce at specific wavelengths: porphyrins (red) and pyoverdines (cyan). The device detects bacteria in the wound bed at a level greater than 104 by measuring the amounts of red and or cyan fluorescence. A robust body of literature has demonstrated that elevated bacterial levels impede wound healing. The MiX can detect elevated bacteria burden in a wound allowing the clinician to address the infection. In addition, the device can guide advanced wound therapies such as antibiofilm agents, negative wound pressure therapy and preparation of the wound bed for grafting.

Paper Details

Date Published: 4 March 2020
PDF: 9 pages
Proc. SPIE 11223, Photonic Diagnosis, Monitoring, Prevention, and Treatment of Infections and Inflammatory Diseases 2020, 112230F (4 March 2020); doi: 10.1117/12.2550307
Show Author Affiliations
Thomas E. Serena, SerenaGroup Research Foundation (United States)


Published in SPIE Proceedings Vol. 11223:
Photonic Diagnosis, Monitoring, Prevention, and Treatment of Infections and Inflammatory Diseases 2020
Tianhong Dai; Jürgen Popp; Mei X. Wu M.D., Editor(s)

© SPIE. Terms of Use
Back to Top
PREMIUM CONTENT
Sign in to read the full article
Create a free SPIE account to get access to
premium articles and original research
Forgot your username?
close_icon_gray